Sellas Life Sciences Group (SLS) is a high-conviction buy due to imminent catalysts, strong institutional backing, and a crucial cash infusion, despite significant binary risk.
Source Post
Is Sellas Life Sciences Group Inc SLS A Good Time To Buy Now? SLS Stock Analysis
Mar 15, 2026
The podcast discusses Sellas Life Sciences Group (SLS), a clinical-stage biopharma company with a massive one-year return of over 323%. Despite having zero revenue and significant net losses, the company is on the verge of a Phase 3 trial readout for its AML maintenance therapy (GPS) and has promising Phase 2 data for its CDK9 inhibitor (SLS00009). A recent $31 million warrant exercise provides crucial runway, and institutional backing from BlackRock and insider buying add to the bullish case. However, the binary nature of the Phase 3 trial presents significant risk.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
SLSbuy opened Mar 15, 2026
+87.90%